

DAFTAR PUSTAKA

- Akarapatima, K., Chang, A., Prateepchaiboon, T., Pungpipattrakul, N., Songjamrat, A., Pakdeejit, S., *et al.* 2022. Comparison of Overall Survival between Transarterial Chemoembolization and Best Supportive Care in Intermediate-Stage Hepatocellular Carcinoma. *Asian Pacific journal of cancer prevention : APJCP*, 23(9), 3173–3178. <https://doi.org/10.31557/APJCP.2022.23.9.3173>
- Balta, S. dan Ozturk, C. 2015. The platelet-lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. *Platelets*, 26(7), 680–681. <https://doi.org/10.3109/09537104.2014.979340>
- Brar, G., Greten, TF., Graubard, BI., McNeel, TS., Petrick, JL., McGlynn, KA. 2020. Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. *Hepatology Communications*, Vol. 4. <https://doi.org/10.1002/hep4.1564>
- Bugada, D., Allegri, M., Lavand'homme, P., De Kock, M., dan Fanelli, G. 2014. Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients. *BioMed research international*, 2014, 142425. <https://doi.org/10.1155/2014/142425>
- Cammà, C., dan Cabibbo, G. 2009. Prognostic scores for hepatocellular carcinoma: none is the winner. *Liver international : official journal of the International Association for the Study of the Liver*, 29(4), 478–480. <https://doi.org/10.1111/j.1478-3231.2009.01994.x>
- Dhanasekaran, R., Bandoh, S., dan Roberts, L. R. 2016. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. *F1000Research*, 5, F1000 Faculty Rev-879. <https://doi.org/10.12688/f1000research.6946.1>
- Dorn, D. P., Bryant, M. K., Zarzour, J., Smith, J. K., Redden, D. T., Saddekni, S., *et al.* 2014. Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. *HPB : the official journal of the International Hepato Pancreato Biliary Association*, 16(7), 648–655. <https://doi.org/10.1111/hpb.12194>
- Duyar, S.S., Solak, Y., Tekis, D., Karakaya, J., Kuscu, F., Erarslan, A. 2016. Platelet to Lymphocyte Ratio as a Novel Prognostic Marker in Male Patients with Chronic Obstructive Pulmonary Disease. *International Journal of Respiratory and Pulmonary Medicine* 3:043.

- El-Fattah, MA., Aboelmagd, M., Elhamouly, M. 2017. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study. *United European Gastroenterology Journal* 5(2). <https://doi.org/10.1177/2050640616659024>
- El-Serag H. B. 2004. Hepatocellular carcinoma: recent trends in the United States. *Gastroenterology*, 127(5 Suppl 1), S27–S34. <https://doi.org/10.1053/j.gastro.2004.09.013>
- El-Serag, H. B. dan Rudolph, K. L. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 132, 2557–2576, <https://doi.org/10.1053/j.gastro.2007.04.061>
- European Association For The Study Of The Liver dan European Organisation For Research And Treatment Of Cancer. 2012. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *Journal of hepatology*, 56(4), 908–943. <https://doi.org/10.1016/j.jhep.2011.12.001>
- Ghouri, Y. A., Mian, I., dan Rowe, J. H. 2017. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. *Journal of carcinogenesis*, 16, 1. https://doi.org/10.4103/jcar.JCar_9_16
- Gray, S. H., White, J. A., Li, P., Kilgore, M. L., Redden, D. T., Abdel Aal, A. K., *et al.* 2017. A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy. *Journal of vascular and interventional radiology : JVIR*, 28(2), 231–237.e2. <https://doi.org/10.1016/j.jvir.2016.09.022>
- Huang, X. Z., Chen, W. J., Zhang, X., Wu, C. C., Zhang, C. Y., Sun, S. S., *et al.* 2017. An Elevated Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Colorectal Cancer: A Meta-Analysis. *Disease markers*, 2017, 1053125. <https://doi.org/10.1155/2017/1053125>
- Hsu, CY., Lee, YH., Hsia, CY., Huang, YH., Su, CW., Lin, HC. 2013. Performance Status in Patients With Hepatocellular Carcinoma: Determinants, Prognostic Impact, and Ability to Improve the Barcelona Clinic Liver Cancer System. *HEPATOLOGY*, Vol. 57, No. 1. <https://doi.org/10.1002/hep.25950>
- Hung, Y. W., Lee, I. C., Chi, C. T., Lee, R. C., Liu, C. A., Chiu, N. C., *et al.* 2021. Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular

Carcinoma: The Seven-Eleven Criteria. *Liver Cancer*.
<https://doi.org/10.1159/000517393>

Kaibori, M., Yoshii, K., Yokota, I., Hasegawa, K., Nagashima, F., Kubo, S. 2017. Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma. *Annals of Surgery* Volume 20, No. 20.
<https://doi:10.1097/SLA.0000000000002526>

Kinoshita, A., Onoda, H., Imai, N., Iwaku, A., Oishi, M., Fushiya, N., *et al.* 2012. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. *British journal of cancer*, 107(6), 988–993. <https://doi.org/10.1038/bjc.2012.354>

Kong, J. Y., Li, S. M., Fan, H. Y., Zhang, L., Zhao, H. J., dan Li, S. M. 2018. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. *Medicine*, 97(33), e11872.
<https://doi.org/10.1097/MD.00000000000011872>

Kudo, M., Han, K. H., Ye, S. L., Zhou, J., Huang, Y. H., Lin, S. M., *et al.* 2020. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. *Liver cancer*, 9(3), 245–260. <https://doi.org/10.1159/000507370>

Liaw, F. Y., Huang, C. F., Chen, W. L., Wu, L. W., Peng, T. C., Chang, Y. W., *et al.* 2017. Higher Platelet-to-Lymphocyte Ratio Increased the Risk of Sarcopenia in the Community-Dwelling Older Adults. *Scientific reports*, 7(1), 16609.
<https://doi.org/10.1038/s41598-017-16924-y>

Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., *et al.* 2021. Hepatocellular carcinoma. *Nature reviews. Disease primers*, 7(1), 6.
<https://doi.org/10.1038/s41572-020-00240-3>

Lopes, FdLM., Coelho, FF., Kruger, JAP., Fonseca, GM., Araujo, RLCd., Jeismann, VB. 2016. Influence of Hepatocellular Carcinoma Etiology in the survival After resection. *ABCD Arq Bras Cir Dig* ;29(2):105-108.
<https://doi.org/10.1590/0102-6720201600020010>

Ma, W., Zhang, P., Qi, J., Gu, L., Zang, M., Yao, H., *et al.* 2016. Prognostic value of platelet to lymphocyte ratio in hepatocellular carcinoma: A meta-analysis. *Scientific Reports*, 6, 16–18. <https://doi.org/10.1038/srep35378>

- Mahassadi, A. K., Anzouan-Kacou Kissi, H., dan Attia, A. K. 2021. The Prognostic Values of Neutrophil-to-lymphocyte Ratio and Platelet-to-Lymphocyte Ratio at Baseline in Predicting the In-hospital Mortality in Black African Patients with Advanced Hepatocellular Carcinoma in Palliative Treatment: A Comparative Cohort Study. *Hepatic medicine : evidence and research*, 13, 123–134. <https://doi.org/10.2147/HMER.S333980>
- Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., *et al.* 2018. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology (Baltimore, Md.)*, 68(2), 723–750. <https://doi.org/10.1002/hep.29913>
- Matsuzaki, K., Murata, M., Yoshida, K., Sekimoto, G., Uemura, Y., Sakaida, N., *et al.* 2007. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. *Hepatology (Baltimore, Md.)*, 46(1), 48–57. <https://doi.org/10.1002/hep.21672>
- Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., *et al.* 2009. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *The Lancet. Oncology*, 10(1), 35–43. [https://doi.org/10.1016/S1470-2045\(08\)70284-5](https://doi.org/10.1016/S1470-2045(08)70284-5)
- McGlynn, K. A., Petrick, J. L., dan El-Serag, H. B. 2021. Epidemiology of Hepatocellular Carcinoma. *Hepatology (Baltimore, Md.)*, 73 Suppl 1(Suppl 1), 4–13. <https://doi.org/10.1002/hep.31288>
- McMillan DC. 2009. Systemic inflammation, nutritional status and survival in patients with cancer. *Curr Opin Clin Nutr Metab Care*, 2009;12:223-6.
- Meng, X., Wei, G., Chang, Q., Peng, R., Shi, G., Zheng, P., *et al.* 2016. The platelet-to-lymphocyte ratio, superior to the neutrophil-to-lymphocyte ratio, correlates with hepatitis C virus infection. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*, 45, 72–77. <https://doi.org/10.1016/j.ijid.2016.02.025>
- Mirici-Cappa, F., Gramenzi, A., Santi, V., Zambruni, A., Di Micoli, A., Frigerio, M., *et al.* 2010. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. *Gut*, 59(3), 387–396. <https://doi.org/10.1136/gut.2009.194217>

- Müller, L., Stoehr1, F., Kunz, A. M., Hahn, F., Weinmann, A., Kloeckner, R. 2021. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. *Journal of Hepatocellular Carcinoma*: 8 403–419. <https://doi.org/10.2147/JHC.S28573>
- Nishikawa, H., Kita, R., Kimura, T., Ohara, Y., Takeda, H., Sakamoto, A., *et al.* 2014. Transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: clinical outcome and safety in elderly patients. *Journal of Cancer*, 5(7), 590–597. <https://doi.org/10.7150/jca.9413>
- Noviyan, R., Ratnasari, N., dan Triwikatmani C. 2022. Analisis Kesintasan Pasien Karsinoma Sel Hati Yang Menjalani *Transarterial Chemoembolization* Berdasarkan Kriteria *Up To Seven*. (Tesis Subspesialis, Universitas Gadjah Mada). <https://etd.repository.ugm.ac.id/>
- Palumbo, J. S., Talmage, K. E., Massari, J. V., La Jeunesse, C. M., Flick, M. J., Kombrinck, K. W., *et al.* 2005. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. *Blood*, 105(1), 178–185. <https://doi.org/10.1182/blood-2004-06-2272>
- Petrick, J. L., Florio, A. A., Znaor, A., Ruggieri, D., Laversanne, M., Alvarez, C. S., *et al.* 2020. International trends in hepatocellular carcinoma incidence, 1978-2012. *International journal of cancer*, 147(2), 317–330. <https://doi.org/10.1002/ijc.32723>
- Pinter, M., Trauner, M., Peck-Radosavljevic, M., dan Sieghart, W. 2016. Cancer and liver cirrhosis: implications on prognosis and management. *ESMO open*, 1(2), e000042. <https://doi.org/10.1136/esmoopen-2016-000042>
- Plantureux, L., Mège, D., Crescence, L., Dignat-George, F., Dubois, C., dan Panicot-Dubois, L. 2018. Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis. *Cancers*, 10(11), 441. <https://doi.org/10.3390/cancers10110441>
- PPHI. 2017. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Jakarta: Perhimpunan Peneliti Hati Indonesia.
- PPHI. 2021. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Jakarta: Perhimpunan Peneliti Hati Indonesia.
- Raoul, JL., Forner, A., Bolondi, L., Cheung, TT., Kloeckner, R., de Baere, T. 2019. Updated use of TACE for hepatocellular carcinoma treatment: How and when to

use it based on clinical evidence. *Cancer Treatment Reviews* 72; 28–36.
<https://doi.org/10.1016/j.ctrv.2018.11.002>

Rebonato, A., Graziosi, L., Maiettini, D., Marino, E., De Angelis, V., Brunese, L., *et al.* 2017. Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. *Gastroenterology research and practice*, 2017, 4164130.
<https://doi.org/10.1155/2017/4164130>

Scaffaro, L. A., Stella, S. F., Alvares-Da-Silva, M. R., dan Kruel, C. D. 2015. Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma. *World journal of hepatology*, 7(3), 628–632. <https://doi.org/10.4254/wjh.v7.i3.628>

Silk, T., Silk, M., dan Wu, J. 2022. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. *World journal of gastroenterology*, 28(23), 2561–2568. <https://doi.org/10.3748/wjg.v28.i23.2561>

Stoiber, D dan Assinger, A. 2020. Platelet-Leukocyte Interplay in Cancer Development and Progression. *Cells*, 9(4):855.
<https://doi.org/10.3390/cells9040855>

Suresh, D., Srinivas, A. N., dan Kumar, D. P. 2020. Etiology of hepatocellular carcinoma: special focus on fatty liver disease. *Frontiers in Oncology*, 10, 601710.

Suresh, D., Srinivas, A. N., dan Kumar, D. P. 2020. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. *Frontiers in oncology*, 10, 601710. <https://doi.org/10.3389/fonc.2020.601710>

Suzuki, K., Aiura, K., Ueda, M., dan Kitajima, M. 2004. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. *Pancreas*, 29(2), 132–140. <https://doi.org/10.1097/00006676-200408000-00008>

Szkandera, J., Gerger, A., Liegl-Atzwanger, B., Absenger, G., Stotz, M., Samonigg, H., *et al.* 2013. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. *British Journal of Cancer*, 109(9), 2316–2322. <https://doi.org/10.1038/bjc.2013.595>

Tangkijvanich, P., Mahachai, V., Suwangool, P., Poovorawan, Y. 2004. Gender difference in clinicopathologic features and survival of patients with

hepatocellular carcinoma. *World Journal of Gastroenterology*, Vol. 10, No.11.
<https://doi:10.3748/wjg.v10.i11.1547>

Tian, X. C., Liu, X. L., Zeng, F. R., Chen, Z., dan Wu, D. H. 2016. Platelet-to-lymphocyte ratio acts as an independent risk factor for patients with hepatitis B virus-related hepatocellular carcinoma who received transarterial chemoembolization. *European review for medical and pharmacological sciences*, 20(11), 2302–2309.

Tunissiolli, N. M., Castanhole-Nunes, M. M. U., Biselli-Chicote, P. M., Pavarino, E. C., da Silva, R. F., da Silva, R. D. C. M. A., Goloni-Bertollo, E. M. 2017. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. *Asian Pacific Journal of Cancer Prevention*, Vol 18; 863-872. <https://doi:10.22034/APJCP.2017.18.4.863>

Wada, Y., Nakashima, O., Kutami, R., Yamamoto, O. dan Kojiro, M. 1998. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. *Hepatology (Baltimore, Md.)* 27, 407–414.
<https://doi.org/10.1002/hep.510270214>

Wang, Y., Attar, B. M., Fuentes, H. E., Jaiswal, P., dan Tafur, A. J. 2017. Evaluation of the prognostic value of platelet to lymphocyte ratio in patients with hepatocellular carcinoma. *Journal of Gastrointestinal Oncology*, 8(6), 1065–1071. <https://doi.org/10.21037/jgo.2017.09.06>

White, J. A., Redden, D. T., Bryant, M. K., Dorn, D., Saddekni, S., Abdel Aal, A. K., *et al.* 2014. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. *HPB : the official journal of the International Hepato Pancreato Biliary Association*, 16(12), 1095–1101.
<https://doi.org/10.1111/hpb.12313>

Xue, T. C., Jia, Q. A., Ge, N. L., Zhang, B. H., Wang, Y. H., Ren, Z. G., *et al.* 2015. The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*, 36(8), 6045–6051. <https://doi.org/10.1007/s13277-015-3281-x>

Yang, Y., Wang, M. C., Tian, T., Huang, J., Yuan, S. X., Liu, L., *et al.* 2020. A High Preoperative Platelet-Lymphocyte Ratio Is a Negative Predictor of Survival After Liver Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Study. *Frontiers in oncology*, 10, 576205.
<https://doi.org/10.3389/fonc.2020.576205>

- Yasui, Y., Tsuchiya, K., Kurosaki, M., Takeguchi, T., Takeguchi, Y., Okada, M., *et al.* 2017. Up-to-seven criteria as a useful Predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after the initial conventional TACE: Predictive value of up-to-seven criteria. *Hepatology Research* 48(6). <https://doi:10.1111/hepr.13048>
- Zhang, L., Hong, W., Wang, Z., Zheng, C., Liang, B., dan Shi, H. 2023. Safety and Effectiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Aged Greater versus Less Than 80 Years. *Clinical interventions in aging*, 18, 1883–1892. <https://doi.org/10.2147/CIA.S429259>
- Zhang, Y. J., Chen, M. S., Chen, Y., Lau, W. Y., & Peng, Z. 2021. Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma. *JAMA network open*, 4(9), e2126992. <https://doi.org/10.1001/jamanetworkopen.2021.26992>
- Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., *et al.* 2020. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). *Liver cancer*, 9(6), 682–720. <https://doi.org/10.1159/000509424>